Shenzhen Cell Valley 2024 highlights work inventory - Enterprise
In 2024, the number of partners in Shenzhen Cell Valley achieved significant growth. We have not only consolidated our market position in South China, but also expanded our cooperation network to the whole country and even overseas. Shenzhen Cell Valley has established cooperative relations with a number of leading biomedical companies in China, and the cooperation is not only limited to the research and development of cell therapy technology, but also covers many fields such as gene therapy, cell preparation, and clinical research.
The following is the inventory of the second highlights of Shenzhen Cell Valley 2024 - Serving customer enterprises (ranked in no particular order, only some cooperative enterprises are listed) :
1. Fosun Kairos (Shanghai) Biotechnology Co., LTD
Fosun Kairos (Shanghai) Biotechnology Co., Ltd. was established in 2017 and is a high-tech biomedical enterprise under Fosun Pharmaceutical. Since its establishment, with the mission of "focusing on healing and brightening life", Fosun Kairos is committed to the research and development, industrialization and commercialization of tumor cell therapy products, with the vision of becoming the most valuable leader in cell and gene therapy. In June 2021, Fosun Kairos was approved to market China's first CAR T cell therapy product, Yikaida ® (Akilencel injection). In June 2023, a new indication (adult large B-cell lymphoma that does not respond to first-line immunochemotherapy or relapsed within 12 months after first-line immunochemotherapy) was approved for marketing. The successful launch of IKAIda ® officially opened the first year of CAR-T therapy in China and continued to lead the high-quality development of lymphoma therapy.
2. Shanghai Yaoming Junuo Biomedical Research and Development Co., LTD
Geminol is an independent, innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products, and is committed to innovation as the leader in cellular immunotherapy. Founded in 2016, Pharming Juno has successfully built an internationally leading comprehensive product development platform for cellular immunotherapy, as well as a pipeline of cellular immunotherapy products covering hematologic tumors, solid tumors and autoimmune diseases. Pharming Juno is committed to bringing the hope of cure to Chinese and even global patients with breakthrough and high-quality cell immunotherapy products, and leading the healthy and standardized development of China's cell immunotherapy industry.
3. Hangzhou Qihan Biotechnology Co., LTD
Hangzhou Qihan Biotech co.,Ltd, referred to as Qihan Biotech Co., LTD, was established in 2017 and is located in Hangzhou, Zhejiang Province. It is a biomedical company with gene technology as its platform. Yang Luhan, Executive Director and General Manager.
Kaisin utilizes world-leading high-throughput gene-editing technology combined with expertise in transplant immunology to create immunologically advantageous allogeneic cell and xenogenic organ therapies for the treatment of cancer, organ failure and other important medical conditions. The main technology multi-gene editing platform, transplant immunity compatible platform.
4. Boe Technology Group Co., LTD
Founded in April 1993, BOE Technology Group Co., LTD. (BOE) is a leading innovative enterprise in the Internet of Things, providing smart port products and professional services for information interaction and human health, and forming a semiconductor display as the core. The "1+4+N+ ecological chain" business architecture of Internet of Things innovation, sensors and solutions, MLED, and smart medical and industrial integration development. Boe Central Research Institute and BOE Regenerative Medicine Technology Co., Ltd. under BOE Technology Group have established a presence in the field of cell and gene therapy, and have applied Shenzhen Cell Valley virus vector and cell product preparation services to develop new cell products.
5. Guangzhou Doublle Bioproduct Co., LTD
Guangzhou Doublle Bioproduct Co., LTD. was founded by Dr. Huang Wenlin, A distinguished national expert, rotating President of the Asia Pacific Cell and Gene Therapy Association, special allowance expert of The State Council, Outstanding Talent of Guangzhou Development Zone (Certificate A), Professor of Cancer Prevention Center of Sun Yat-sen University and Honorary Professor of the Chinese University of Hong Kong. Focusing on the development and transformation of gene therapy, immune cell therapy, vaccines and other genetic engineering technology applications, Dabo is a national high-tech enterprise. Long-term unremitting efforts have enabled Dabo to form a sustainable development pipeline in the field of gene therapy drug research and development and transformation.
6. Shenzhen Leman Biotechnology Co., LTD
Shenzhen Leman Biotechnology Co., Ltd. is a clinical stage immune metabolism therapy drug development company, co-founded by Professor Tang Li team of Swiss Federal Institute of Technology Lausanne and Jingtai Technology. Based on the innovative technology of immune metabolism reprogramming + cutting-edge artificial intelligence, the company focuses on the development, production and commercialization of novel tumor immunotherapy drugs.
7. Shenzhen Sanqi Biotechnology Co., LTD
Founded in 2013, Sanqi has been committed to product development based on induced pluripotent stem cells (iPSC) and gene editing technology platform, focusing on the development of universal and off-the-shelf cell therapy products based on human iPSC, and currently focuses on the treatment of tumor and autoimmune diseases.
8. Zhongshan Kangfang Biomedicine Co., LTD
Founded in 2012, Kangfang Bio is a biopharmaceutical company integrating research, development, production and commercialization of innovative new antibody drugs that are affordable to global patients. It was officially listed on the main board of the Stock Exchange of Hong Kong Limited on April 24, 2020.
9. Shenzhen Saiqiao Future Biotechnology Co., LTD
Saiqiao Biology was founded in March 2020 by a number of outstanding doctoral students from the Department of Precision Instruments of Tsinghua University and Professor Zhang Youming, academician of the German National Academy of Science and Engineering and academician of the European Academy of Sciences.
With the mission of "integration, co-creation and sharing, accompanying customers' growth", we focus on the source technology innovation and localization of key manufacturing technologies and complete sets of core equipment in the upstream of the cell and gene therapy (CGT) industry, master the initiative and pricing power of the industry development, and realize the "one-key preparation and one-key release" of cell and gene drugs. Promote cell gene therapy for cancer and degenerative diseases from millions of yuan to tens of millions of yuan, benefiting more patients.
10. Jiangsu Hengrui Pharmaceutical Co., LTD
Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Pharmaceutical is an innovative international pharmaceutical company focusing on the research and development, production and promotion of high-quality drugs, focusing on anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, neurological diseases and other fields of new drug research and development. It is one of the most innovative pharmaceutical leading enterprises in China.
11. Dongguan Dongyangguang Biological Drug R&D Co., LTD
Dongyang is a high-tech large-scale joint-stock enterprise full of hope, focusing on industry and building a century-old foundation, with nearly 30,000 employees. Mainly engaged in "electronic new materials", "biomedicine" and "health" three major industries, the existing Guangdong Dongguan, Guangdong Shaoguan, Hubei Yichang, Zhejiang Dongyang, Inner Mongolia Wulanchabu, Guizhou Zunyi, Tibet Nyingchi seven bases; It has two listed companies, East Sunshine (600673.SH) and East Sunshine Changjiang Pharmaceutical (01558.HK). Up to now, the total assets of the group have exceeded 80 billion yuan, and the cumulative tax payment has exceeded 20 billion yuan, which has entered the top 500 private enterprises in China.
Guided by medium and long-term strategic planning, the company takes the Board of Directors of the Group as the core management organization, implements the dual-engine strategy of "innovation" + "internationalization", vigorously develops the innovative real economy, and constantly promotes the company to achieve higher quality sustainable development!
12. Shanghai Enkai Cell Technology Co., LTD
Enkesser is committed to the source innovation of immune cell drugs, using synthetic immunological technologies such as logic loop, feedback switch and intelligent manipulation to quantify, control and intelligentize NK cell drugs through gene manipulation, so as to artificially create NK cells that meet different clinical needs, which will bring new hope to patients with cancer and many other diseases.
Nkesai has the world's top scientific research and development team, and has accumulated more than 30 years in the research and application development of NK cell biology. At the same time, the team has experienced R&D and management personnel in all key links of the tumor immunotherapy innovation chain, and has long-term accumulation in the development, production and application of NK cell drugs, which will become a model for cell drugs with independent intellectual property rights in China to the world.
In the upcoming New Year, Shenzhen Cell Valley will continue to uphold the concept of "cells benefit sentient beings, genes create the future", and continue to deepen the cooperation with cooperative enterprises to promote the development of cell and gene therapy technology. We look forward to continuing to work with companies in the coming days to open a new chapter in the field of biomedicine.
The following is the inventory of the second highlights of Shenzhen Cell Valley 2024 - Serving customer enterprises (ranked in no particular order, only some cooperative enterprises are listed) :
1. Fosun Kairos (Shanghai) Biotechnology Co., LTD
Fosun Kairos (Shanghai) Biotechnology Co., Ltd. was established in 2017 and is a high-tech biomedical enterprise under Fosun Pharmaceutical. Since its establishment, with the mission of "focusing on healing and brightening life", Fosun Kairos is committed to the research and development, industrialization and commercialization of tumor cell therapy products, with the vision of becoming the most valuable leader in cell and gene therapy. In June 2021, Fosun Kairos was approved to market China's first CAR T cell therapy product, Yikaida ® (Akilencel injection). In June 2023, a new indication (adult large B-cell lymphoma that does not respond to first-line immunochemotherapy or relapsed within 12 months after first-line immunochemotherapy) was approved for marketing. The successful launch of IKAIda ® officially opened the first year of CAR-T therapy in China and continued to lead the high-quality development of lymphoma therapy.
2. Shanghai Yaoming Junuo Biomedical Research and Development Co., LTD
Geminol is an independent, innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products, and is committed to innovation as the leader in cellular immunotherapy. Founded in 2016, Pharming Juno has successfully built an internationally leading comprehensive product development platform for cellular immunotherapy, as well as a pipeline of cellular immunotherapy products covering hematologic tumors, solid tumors and autoimmune diseases. Pharming Juno is committed to bringing the hope of cure to Chinese and even global patients with breakthrough and high-quality cell immunotherapy products, and leading the healthy and standardized development of China's cell immunotherapy industry.
3. Hangzhou Qihan Biotechnology Co., LTD
Hangzhou Qihan Biotech co.,Ltd, referred to as Qihan Biotech Co., LTD, was established in 2017 and is located in Hangzhou, Zhejiang Province. It is a biomedical company with gene technology as its platform. Yang Luhan, Executive Director and General Manager.
Kaisin utilizes world-leading high-throughput gene-editing technology combined with expertise in transplant immunology to create immunologically advantageous allogeneic cell and xenogenic organ therapies for the treatment of cancer, organ failure and other important medical conditions. The main technology multi-gene editing platform, transplant immunity compatible platform.
4. Boe Technology Group Co., LTD
Founded in April 1993, BOE Technology Group Co., LTD. (BOE) is a leading innovative enterprise in the Internet of Things, providing smart port products and professional services for information interaction and human health, and forming a semiconductor display as the core. The "1+4+N+ ecological chain" business architecture of Internet of Things innovation, sensors and solutions, MLED, and smart medical and industrial integration development. Boe Central Research Institute and BOE Regenerative Medicine Technology Co., Ltd. under BOE Technology Group have established a presence in the field of cell and gene therapy, and have applied Shenzhen Cell Valley virus vector and cell product preparation services to develop new cell products.
5. Guangzhou Doublle Bioproduct Co., LTD
Guangzhou Doublle Bioproduct Co., LTD. was founded by Dr. Huang Wenlin, A distinguished national expert, rotating President of the Asia Pacific Cell and Gene Therapy Association, special allowance expert of The State Council, Outstanding Talent of Guangzhou Development Zone (Certificate A), Professor of Cancer Prevention Center of Sun Yat-sen University and Honorary Professor of the Chinese University of Hong Kong. Focusing on the development and transformation of gene therapy, immune cell therapy, vaccines and other genetic engineering technology applications, Dabo is a national high-tech enterprise. Long-term unremitting efforts have enabled Dabo to form a sustainable development pipeline in the field of gene therapy drug research and development and transformation.
6. Shenzhen Leman Biotechnology Co., LTD
Shenzhen Leman Biotechnology Co., Ltd. is a clinical stage immune metabolism therapy drug development company, co-founded by Professor Tang Li team of Swiss Federal Institute of Technology Lausanne and Jingtai Technology. Based on the innovative technology of immune metabolism reprogramming + cutting-edge artificial intelligence, the company focuses on the development, production and commercialization of novel tumor immunotherapy drugs.
7. Shenzhen Sanqi Biotechnology Co., LTD
Founded in 2013, Sanqi has been committed to product development based on induced pluripotent stem cells (iPSC) and gene editing technology platform, focusing on the development of universal and off-the-shelf cell therapy products based on human iPSC, and currently focuses on the treatment of tumor and autoimmune diseases.
8. Zhongshan Kangfang Biomedicine Co., LTD
Founded in 2012, Kangfang Bio is a biopharmaceutical company integrating research, development, production and commercialization of innovative new antibody drugs that are affordable to global patients. It was officially listed on the main board of the Stock Exchange of Hong Kong Limited on April 24, 2020.
9. Shenzhen Saiqiao Future Biotechnology Co., LTD
Saiqiao Biology was founded in March 2020 by a number of outstanding doctoral students from the Department of Precision Instruments of Tsinghua University and Professor Zhang Youming, academician of the German National Academy of Science and Engineering and academician of the European Academy of Sciences.
With the mission of "integration, co-creation and sharing, accompanying customers' growth", we focus on the source technology innovation and localization of key manufacturing technologies and complete sets of core equipment in the upstream of the cell and gene therapy (CGT) industry, master the initiative and pricing power of the industry development, and realize the "one-key preparation and one-key release" of cell and gene drugs. Promote cell gene therapy for cancer and degenerative diseases from millions of yuan to tens of millions of yuan, benefiting more patients.
10. Jiangsu Hengrui Pharmaceutical Co., LTD
Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Pharmaceutical is an innovative international pharmaceutical company focusing on the research and development, production and promotion of high-quality drugs, focusing on anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, neurological diseases and other fields of new drug research and development. It is one of the most innovative pharmaceutical leading enterprises in China.
11. Dongguan Dongyangguang Biological Drug R&D Co., LTD
Dongyang is a high-tech large-scale joint-stock enterprise full of hope, focusing on industry and building a century-old foundation, with nearly 30,000 employees. Mainly engaged in "electronic new materials", "biomedicine" and "health" three major industries, the existing Guangdong Dongguan, Guangdong Shaoguan, Hubei Yichang, Zhejiang Dongyang, Inner Mongolia Wulanchabu, Guizhou Zunyi, Tibet Nyingchi seven bases; It has two listed companies, East Sunshine (600673.SH) and East Sunshine Changjiang Pharmaceutical (01558.HK). Up to now, the total assets of the group have exceeded 80 billion yuan, and the cumulative tax payment has exceeded 20 billion yuan, which has entered the top 500 private enterprises in China.
Guided by medium and long-term strategic planning, the company takes the Board of Directors of the Group as the core management organization, implements the dual-engine strategy of "innovation" + "internationalization", vigorously develops the innovative real economy, and constantly promotes the company to achieve higher quality sustainable development!
12. Shanghai Enkai Cell Technology Co., LTD
Enkesser is committed to the source innovation of immune cell drugs, using synthetic immunological technologies such as logic loop, feedback switch and intelligent manipulation to quantify, control and intelligentize NK cell drugs through gene manipulation, so as to artificially create NK cells that meet different clinical needs, which will bring new hope to patients with cancer and many other diseases.
Nkesai has the world's top scientific research and development team, and has accumulated more than 30 years in the research and application development of NK cell biology. At the same time, the team has experienced R&D and management personnel in all key links of the tumor immunotherapy innovation chain, and has long-term accumulation in the development, production and application of NK cell drugs, which will become a model for cell drugs with independent intellectual property rights in China to the world.
In the upcoming New Year, Shenzhen Cell Valley will continue to uphold the concept of "cells benefit sentient beings, genes create the future", and continue to deepen the cooperation with cooperative enterprises to promote the development of cell and gene therapy technology. We look forward to continuing to work with companies in the coming days to open a new chapter in the field of biomedicine.
